BriaCell Therapeutics Reports Preliminary Survival And Clinical Benefit Data In A New Subset Of Advanced Breast Cancer Patients Treated With BriaCell's Bria-IMT Regimen: Patients That Have Developed Resistance To Antibody-Drug Conjugates
BriaCell Therapeutics Reports Preliminary Survival And Clinical Benefit Data In A New Subset Of Advanced Breast Cancer Patients Treated With BriaCell's Bria-IMT Regimen: Patients That Have Developed Resistance To Antibody-Drug Conjugates
BriaCell Therapeutics报告了新一组接受BriaCell的Bria-imt方案治疗的晚期乳腺癌患者的初步生存和临床益处数据：对抗体药物偶联物产生耐药性的患者
- In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell's combination regimen exceeded that of similar studies*
-
Progression Free Survival (PFS) was similar or better than last regimen in 40% of the patients highlighting clinical efficacy
- Disease control rate of 40% was observed in evaluable patients further indicating clinical benefit
- 在抗体-药物偶联物（ADC）难治患者的子集中，BriaCell联合疗法的总生存率（OS）数据超过了类似研究的数据*
-
在强调临床疗效的40％的患者中，无进展生存（PFS）与上一次疗法相似或更好
- 在可评估的患者中观察到疾病控制率为40％，这进一步表明了临床益处